March 24, 2026

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

The ASCO Post

March 24, 2026

Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer

Intravesical treatment with the investigational immunotherapy cretostimogene grenadenorepvec (CG0070) demonstrated “strong” high-grade recurrence-free survival rates in patients with high-risk, papill...

The ASCO Post

March 24, 2026

No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma

Recurrence-free survival was similar between adjuvant therapy with the PD-1 inhibitor pembrolizumab and placebo in patients with hepatocellular carcinoma who achieved a complete radiologic response af...

The ASCO Post

March 24, 2026

Disease-Free Survival With Gemcitabine Intravesical System in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer

Monotherapy with a gemcitabine intravesical system demonstrated high disease-free survival rates in patients with bacillus Calmette-Guérin-unresponsive papillary-only high-risk non–muscle-invasive bla...

The ASCO Post

March 24, 2026

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

The ASCO Post

March 24, 2026

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...

The ASCO Post

March 24, 2026

Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New U.S. Dietary Guidelines, Survey Finds

“The Surgeon General’s finding that alcohol consumption raises cancer risk gained attention. A clear, strong statement in the dietary guidelines could have amplified that impact—and helped to save liv...

The ASCO Post

March 24, 2026

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...

The ASCO Post

March 23, 2026

Lisocabtagene Maraleucel in Relapsed or Refractory MZL

In a phase II trial (TRANSCEND FL) reported in The Lancet, Palomba et al found that lisocabtagene maraleucel was active in patients with relapsed or refractory marginal zone lymphoma (MZL).

The ASCO Post

March 18, 2026

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

The ASCO Post